CorMedix Inc. (CRMD)
NASDAQ: CRMDHealth CareBiotechnology: Pharmaceutical PreparationsUSD
At close: Oct 7, 4:00 PM ET · Delayed 15 min
CRMD stock chart
Technical analysisKey statistics
All statistics- Market cap
- $567.43M
- P/E (TTM)
- 3.55
- Forward P/E
- 20.80
- EPS (TTM)
- $2.05
- Dividend yield
- None
- 52-week range
- 6.13 – 13.02
- Day range
- 7.18 – 7.31
- Volume / Avg
- 832.89K / 1.06M
- Beta
- —
- Shares outstanding
- 77.94M
52-week range
CRMD stock today
CorMedix (CRMD) closed at $7.28 on Oct 7, essentially unchanged from the prior close, versus the S&P 500's 0.22% decline. At this level, CRMD sits near the bottom of its 52-week range of $6.13 to $13.02: 44.1% below the high, set on Dec 30, 2025 and 18.8% above the low. CRMD is down 37.4% year to date, underperforming the S&P 500 (+14.0%). Over the past 12 months, the stock has lost 34.4%.
CorMedix trades at 3.6x its trailing twelve-month earnings per share of $2.05. Its forward P/E of 20.8x is higher than the trailing multiple, which means analysts expect earnings to decline over the next year.
Summary generated from market data by MetaCap's automated system. Methodology
About CorMedix
Company profileCorMedix Inc., a biopharmaceutical company, focuses on developing and commercializing therapeutic products for life-threatening diseases and conditions in the United States. Its lead product candidate is DefenCath, an antimicrobial catheter lock solution to reduce the incidence of catheter-related bloodstream infections in adult patients with kidney failure. CorMedix Inc.
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- CEO
- Mr. Joseph Todisco MBA
- Headquarters
- Parsippany, NJ
- Employees
- 191
- Website
- cormedix.com
Analyst forecast
ForecastConsensus (6 analysts)
strong_buy
Avg. price target
$15.33+110.58%
- Strong buy 3
- Buy 3
- Hold 0
- Sell 0
- Strong sell 0
Target range
Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.
CorMedix peers
Health Care sector| Company | Price | % Chg | Market cap | Compare |
|---|---|---|---|---|
| STTKShattuck Labs Inc. | 5.66 | -3.50% | $567.55M | vs CRMD |
| EVOEvotec SE ADR | 1.61 | -1.23% | $572.18M | vs CRMD |
| MNPRMonopar Therapeutics Inc. | 83.78 | +5.29% | $562.35M | vs CRMD |
| CTMXCytomX Therapeutics Inc. | 2.55 | -0.39% | $555.64M | vs CRMD |
| AQSTAquestive Therapeutics Inc. | 4.62 | +0.22% | $579.86M | vs CRMD |
| PHATPhathom Pharmaceuticals Inc. | 6.81 | +0.44% | $550.94M | vs CRMD |
| BLSMBlossomHill Therapeutics Inc. | 16.61 | -3.93% | $527.95M | vs CRMD |
| SLNSilence Therapeutics Plc American Depository Share | 9.82 | -0.10% | $610.35M | vs CRMD |
Indexes, lists and sector
CorMedix stock FAQ
What is CorMedix's stock price today?
CRMD last traded at $7.28 as of Oct 7, 4:00 PM EDT, up 0.00% on the day. Prices are delayed at least 15 minutes.
Does CorMedix pay a dividend?
No. CorMedix does not currently pay a regular cash dividend.
What is CRMD's P/E ratio?
CRMD trades at a trailing P/E ratio of 3.55 and a forward P/E of 20.80.
Who is CorMedix's CEO?
Mr. Joseph Todisco MBA is the chief executive officer of CorMedix Inc., which has about 191 employees.
Has CRMD ever split its stock?
Yes. The most recent CRMD stock split was a 1-for-5 split on Mar 26, 2019.
What is the CRMD 52-week high?
The 52-week high for CRMD is $13.02 and the 52-week low is $6.13. The stock is currently 44.1% below its high.